Genmab A (GMAB) Total Current Liabilities (2018 - 2026)

Genmab A (GMAB) has reported Total Current Liabilities for 9 consecutive years, with $1.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 81.24% year-over-year to $1.1 billion; the trailing twelve-month figure through Jun 2026 stood at $1.1 billion (up 81.24% YoY), and the FY2025 full-year result was $1.4 billion, up 91.8% from the prior year.
• Total Current Liabilities retreated to $1.1 billion in Q2 2026 per GMAB's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.4 billion in Q4 2025 and bottomed at $143.5 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $482.4 million across 5 years, with a median of $276.3 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities declined 6.98% in 2022, then surged 188.94% in 2025.
• Over 5 years, Total Current Liabilities stood at $194.4 million in 2022, then climbed by 20.05% to $233.4 million in 2023, then surged by 111.64% to $493.9 million in 2024, then soared by 188.94% to $1.4 billion in 2025, then decreased by 20.11% to $1.1 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $1.1 billion, $1.2 billion, and $1.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.